Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $9.9 million.

  • Rocket Pharmaceuticals' Non-cash Items fell 9051.13% to $9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year decrease of 9051.13%. This contributed to the annual value of $63.3 million for FY2024, which is 7474.28% down from last year.
  • Rocket Pharmaceuticals' Non-cash Items amounted to $9.9 million in Q3 2025, which was down 9051.13% from $6.5 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' 5-year Non-cash Items high stood at $349.4 million for Q1 2021, and its period low was $6.5 million during Q2 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' median Non-cash Items value was $118.8 million (recorded in 2022), while the average stood at $134.1 million.
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Non-cash Items surged by 33327.51% in 2021, and later crashed by 9526.86% in 2025.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' Non-cash Items stood at $128.8 million in 2021, then dropped by 7.8% to $118.8 million in 2022, then skyrocketed by 111.0% to $250.6 million in 2023, then plummeted by 74.74% to $63.3 million in 2024, then crashed by 84.3% to $9.9 million in 2025.
  • Its Non-cash Items stands at $9.9 million for Q3 2025, versus $6.5 million for Q2 2025 and $30.7 million for Q1 2025.